Use of mechanical assist during high-risk PCI and STEMI with cardiogenic shock.

Catheter Cardiovasc Interv

Division of Cardiology, Washington University, School of Medicine, St. Louis, Missouri 63110, USA.

Published: March 2010

Infarct size may be reduced by left ventricular unloading after ST-segment elevation MI (STEMI) in addition to reperfusion therapy. Likewise, high-risk percutaneous coronary intervention (PCI) may benefit from periprocedural support especially in patients with low cardiac output at baseline or when periprocedural hemodynamic deterioration is anticipated. Traditionally, intraaortic balloon-pumps have been used in acute MI with cardiogenic shock. As this modality has limited hemodynamic benefits, new developments have focused on active hemodynamic assist devices. These devices actively unload the left ventricle increasing cardiac output by 2.5-5 L/min and are increasingly easier to implant and monitor. Thus, interventional cardiologists will be able to offer a safer more effective alternative to an increasing patient population with complex cardiac conditions and high-risk PCI.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccd.22366DOI Listing

Publication Analysis

Top Keywords

high-risk pci
8
cardiogenic shock
8
cardiac output
8
mechanical assist
4
assist high-risk
4
pci stemi
4
stemi cardiogenic
4
shock infarct
4
infarct size
4
size reduced
4

Similar Publications

Purpose Of Review: This review assesses the outcomes of coronary interventions in patients with liver cirrhosis and coronary artery disease (CAD), focusing on the clinical challenges posed by cirrhosis-related hemodynamic and coagulopathic changes. It highlights essential considerations for managing these patients, who have an increased risk of adverse events during coronary procedures.

Recent Findings: Recent studies have shown that patients with liver cirrhosis undergoing PCI experience significantly higher mortality rates compared to non-cirrhotic patients, particularly in the context of STEMI and NSTEMI.

View Article and Find Full Text PDF

Introduction: Impella CP is a percutaneous left ventricle assist device used in selected patients undergoing high-risk percutaneous coronary interventions (HR-PCI). To improve outcomes after Impella-supported HR-PCI, institutional Impella programs have been developed.

Objectives: We evaluated the association between the standardized periprocedural management algorithm and outcomes of patients undergoing HR-PCI in the national IMPELLA-PL Registry.

View Article and Find Full Text PDF

Intravascular ultrasound (IVUS) in percutaneous coronary intervention (PCI) has transformed the management of complex higher risk-indicated patients (CHIPs), representing a pivotal advancement in high-risk procedure navigation. IVUS, complementing conventional angiography, provides unparalleled insights into lesion characteristics, plaque morphology, and vessel structure, enhancing the precision of stent placement and postprocedural care for CHIPs. The ongoing trials underscore the pivotal role of IVUS in optimizing procedural accuracy and improving clinical outcomes for high-risk patients, promising exciting new findings.

View Article and Find Full Text PDF

Spontaneous Coronary Dissection Review: A Complex Picture.

Rev Cardiovasc Med

December 2024

Cardiologia, Ospedale Maggiore, 26900 Lodi, Italy.

Spontaneous coronary artery dissection (SCAD) represents a quite rare event but with potentially serious prognostic implications. Meanwhile, SCAD typically presents as an acute coronary syndrome (ACS). Despite the majority of SCAD presentation being characterized by typical ACS signs and symptoms, young age at presentation with an atypical atherosclerotic risk factor profile is responsible for late medical contact and misdiagnosis.

View Article and Find Full Text PDF

Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has garnered significant interest due to its potential cardiovascular benefits, particularly in patients experiencing acute myocardial infarction (AMI) who are undergoing primary percutaneous coronary intervention (PCI). This systematic review aims to evaluate the effectiveness of Empagliflozin in improving clinical outcomes in this patient population. A systematic review of randomized controlled trials (RCTs) was conducted to assess the effects of Empagliflozin on clinical outcomes in patients with AMI undergoing primary PCI.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!